3 Dividend Kings to Buy in November and Never Sell

Source Motley_fool

Key Points

  • Abbott boasts 54 straight years of dividend growth, and plans to spin off its troubled nutrition division could lead to a re-rating of the stock.

  • McDonald's has raised its dividend for 50 years, and the stock should rebound further if turnaround efforts continue to improve results.

  • Floor cleaning equipment maker Tennant has raised its dividend for 55 consecutive years and has a catalyst that could drive a recovery.

  • 10 stocks we like better than Abbott Laboratories ›

Dividend Kings are dividend stocks that have raised their payouts for at least 50 consecutive years. Currently, there are around 59 stocks that meet this criterion. These stocks have strong records in total returns, the returns generated by both price appreciation and dividend payments.

Yet while these high-quality stocks rarely become bargains, Abbott Laboratories (NYSE:ABT), McDonald's (NYSE:MCD), and Tennant (NYSE:TNC) have recently pulled back from their 52-week highs, creating an opportunity to capitalize on recent weakness to start accumulating a long-term position.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

Recent spinoff news bodes well for Abbott Laboratories

Abbott Laboratories has paid a quarterly cash dividend for 102 years and has raised it for 54 consecutive years. The healthcare company's shares currently have a forward dividend yield of around 2.3%, and over the last five years, dividend growth has averaged around 9.4% annually.

However, it's not just Abbott's strengths as a dividend stock that make it a strong buy this month. Consider other recent news, which may pave the way for higher prices.

I'm talking about last month's announcement that the company plans to spin off its nutrition business. This segment, which makes products like Ensure nutritional supplements and Similac infant formula, has contended with both weakening sales and litigation headwinds, and spinning it off could bode very well for what remains of Abbott.

Why? By divesting this business, Abbott can focus on a more focused medical technology (medtech) play, centered on its faster-growing equipment and diagnostics segments.

This stock currently trades for 18 times forward earnings, while comparable medical device stocks trade at price-to-earnings (P/E) ratios in the 20s or higher. If shares re-rate to a higher valuation and its overall earnings and dividend growth rate improve once the nutrition business is spun off, this could potentially lead to strong total returns in the years ahead.

McDonald's is rallying and could see a further comeback

McDonald's shares were hammered hard earlier this year. Mostly because high prices and the financial squeeze facing consumer households due to high inflation raised worries about long-term growth for the Golden Arches.

More recently, however, investors have flocked back to the fast-food stock. This comes on the heels of the company's Q3 2026 earnings release earlier this month. Alongside an earnings beat, management provided upbeat comments on improving performance at its U.S. locations and offered further details on its ongoing turnaround.

Some may view McDonald's recent rally as premature. Still, if further moves to improve fiscal performance prove successful, this Dividend King may have more room to run, given its current valuation relative to its historical valuation. Trading at around 20 times forward earnings today, McDonald's has in the recent past traded at an earnings multiple of 25 to 30.

In the meantime, investors collect the stock's dividend, which it has raised for 50 consecutive years. Backed by a steady stream of franchisee royalty and rent payments, the stock has a forward dividend yield of 2.8%, with annual dividend growth averaging 7.3% over the past five years.

Tennant is a Dividend King and an automation play

Tennant, a manufacturer of floor maintenance and cleaning equipment, is hardly a household name. But just as its products are quietly used to keep commercial and institutional flooring looking its best, this stock has been quietly rewarding investors with annual dividend increases over the last 55 years.

In fact, this month, Tennant just implemented its latest dividend increase, with its quarterly cash payout rising 5% to 32.5 cents per share. Following this increase, Tennant now has a forward dividend yield of around 1.75%. Over the last five years, annual dividend growth has averaged around 6.1%.

Tennant may be the epitome of an "old economy" company, but make no mistake. This is one of the industrial stocks with a strong catalyst in robotics and automation. Its pivot toward selling automated floor-cleaning equipment is already helping drive a resurgence in growth.

Last quarter, revenue increased 6%, while orders increased by 9.5%. While ERP-related technology costs and increased investment in its robotics business are affecting earnings growth, these issues could prove short-lived. In the coming quarters, Tennant's earnings could improve, potentially leading to a rebound in shares.

Trading in the mid-$70s today, the stock stood at north of $100 per share as recently as mid-2024.

Should you buy stock in Abbott Laboratories right now?

Before you buy stock in Abbott Laboratories, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Abbott Laboratories wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $322,605!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $927,581!*

Now, it’s worth noting Stock Advisor’s total average return is 790% — a market-crushing outperformance compared to 202% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 19, 2026.

Thomas Niel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends the following options: long January 2028 $320 calls on McDonald's and short January 2028 $340 calls on McDonald's. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Australian Dollar Today: AUD/USD Falls Below 0.67 After Jobs DataAUD/USD slips below 0.67 after Australia sheds 43,500 jobs. Explore the Australian dollar outlook, key price levels and CFD trading considerations.
Author  Mitrade Team
14 hours ago
AUD/USD slips below 0.67 after Australia sheds 43,500 jobs. Explore the Australian dollar outlook, key price levels and CFD trading considerations.
placeholder
Nvidia delivered another huge beat and strong outlook — so why isn’t the NAS100 surging?Nvidia has delivered another strong earnings beat and raised its outlook, yet the NAS100 is struggling to rally. Explore why investor expectations, AI spending concerns and market sentiment may be limiting the upside, and what Australian traders should watch next.
Author  Mark Garro
17 hours ago
Nvidia has delivered another strong earnings beat and raised its outlook, yet the NAS100 is struggling to rally. Explore why investor expectations, AI spending concerns and market sentiment may be limiting the upside, and what Australian traders should watch next.
placeholder
Market News Today Australia: Gold Breaks US$3,800, Oil Slides and S&P 500 Falls for Fifth SessionGold falls below US$3,800, silver slides 5% and the S&P 500 extends its losing streak. Explore Fed developments and the outlook for Australian traders.
Author  Mitrade Team
18 hours ago
Gold falls below US$3,800, silver slides 5% and the S&P 500 extends its losing streak. Explore Fed developments and the outlook for Australian traders.
placeholder
Silver Price Erased 45 Years of Gains. Will It Crash Further?The silver price fell to $45.14 on Wednesday, a new 2026 low. The drop leaves silver 62% below its January record and back under its 1980 high.Breakout buyers now sit on losses, and former support may
Author  Beincrypto
19 hours ago
The silver price fell to $45.14 on Wednesday, a new 2026 low. The drop leaves silver 62% below its January record and back under its 1980 high.Breakout buyers now sit on losses, and former support may
placeholder
Anthropic Prices IPO at $83: What a $1.5 Trillion Valuation Means for ANT BuyersAnthropic priced its initial public offering (IPO) at $83 a share, above its $70 to $78 range, Bloomberg reported. It also sold more shares than planned, and with a private share sale the deal tops Sp
Author  Beincrypto
19 hours ago
Anthropic priced its initial public offering (IPO) at $83 a share, above its $70 to $78 range, Bloomberg reported. It also sold more shares than planned, and with a private share sale the deal tops Sp
goTop
quote